5D9Q

Crystal Structure of the BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46

Summary for 5D9Q

• Entry DOI: 10.2210/pdb5d9q/pdb
• Related: 4NCO 4TVP 5KZC
• Descriptor: Envelope glycoprotein gp120, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (12 entities in total)
• Functional Keywords: hiv env glycoprotein; broadly neutralizing antibodies; immune system, immune system
• Biological source: Human immunodeficiency virus 1; More
• Total number of polymer chains: 15
• Total formula weight: 473368.32

Authors

Julien, J.-P.,Stanfield, R.L.,Ward, A.B.,Wilson, I.A. (deposition date: 2015-08-18, release date: 2016-08-17, Last modification date: 2024-10-23)

Primary citation

Jardine, J.G.,Sok, D.,Julien, J.P.,Briney, B.,Sarkar, A.,Liang, C.H.,Scherer, E.A.,Henry Dunand, C.J.,Adachi, Y.,Diwanji, D.,Hsueh, J.,Jones, M.,Kalyuzhniy, O.,Kubitz, M.,Spencer, S.,Pauthner, M.,Saye-Francisco, K.L.,Sesterhenn, F.,Wilson, P.C.,Galloway, D.M.,Stanfield, R.L.,Wilson, I.A.,Burton, D.R.,Schief, W.R.
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Plos Pathog., 12:e1005815-e1005815, 2016

PubMed Abstract: An optimal HIV vaccine should induce broadly neutralizing antibodies (bnAbs) that neutralize diverse viral strains and subtypes. However, potent bnAbs develop in only a small fraction of HIV-infected individuals, all contain rare features such as extensive mutation, insertions, deletions, and/or long complementarity-determining regions, and some are polyreactive, casting doubt on whether bnAbs to HIV can be reliably induced by vaccination. We engineered two potent VRC01-class bnAbs that minimized rare features. According to a quantitative features frequency analysis, the set of features for one of these minimally mutated bnAbs compared favorably with all 68 HIV bnAbs analyzed and was similar to antibodies elicited by common vaccines. This same minimally mutated bnAb lacked polyreactivity in four different assays. We then divided the minimal mutations into spatial clusters and dissected the epitope components interacting with those clusters, by mutational and crystallographic analyses coupled with neutralization assays. Finally, by synthesizing available data, we developed a working-concept boosting strategy to select the mutation clusters in a logical order following a germline-targeting prime. We have thus developed potent HIV bnAbs that may be more tractable vaccine goals compared to existing bnAbs, and we have proposed a strategy to elicit them. This reductionist approach to vaccine design, guided by antibody and antigen structure, could be applied to design candidate vaccines for other HIV bnAbs or protective Abs against other pathogens.

PubMed: 27560183
DOI: 10.1371/journal.ppat.1005815

Experimental method

X-RAY DIFFRACTION (4.4 Å)